About 1-2% of the population worldwide.

Obsessive-Compulsive Disorder (OCD)

Recent research indicates that psychedelics, particularly psilocybin, are emerging as potential therapeutic agents in the treatment of Obsessive-Compulsive Disorder (OCD). Early clinical trials demonstrate promising results regarding their efficacy and safety, paving the way for future studies in this field.

What is Obsessive-Compulsive Disorder (OCD)?

Obsessive-Compulsive Disorder (OCD) is characterised by persistent, intrusive thoughts (obsessions) that lead to repetitive behaviours or mental acts (compulsions) aimed at alleviating the distress caused by these obsessions.

The pathophysiology of OCD is believed to involve abnormalities in neural circuits, particularly those involving the orbitofrontal cortex, anterior cingulate cortex, and striatum, with imbalances in neurotransmitter systems, notably serotonin and dopamine.

Common symptoms include excessive cleaning, checking, counting, and arranging, which can significantly impair an individual's daily functioning and quality of life.

Current Treatments

Standard treatments for OCD include selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and sertraline, and cognitive behavioural therapy (CBT), particularly exposure and response prevention.

Psychedelic Effect Matrix

Systematic comparison of compound efficacy and evidence levels for Obsessive-Compulsive Disorder (OCD).

Compound	Magnitude	Evidence	Consistency
Psilocybin Clinical trials indicate a consistent reduction in OCD symptoms with psilocybin in treatment-resistant patients.	Medium	Moderate	Consistent
MDMA Limited research exists on MDMA's effects specifically for OCD, with emerging studies highlighting potential benefits.	Small	Low	Inconsistent
Ketamine Ketamine's antidepressant effects provide some hope, but specific evidence for OCD is currently limited.	Small	Low	Inconsistent

Psilocybin and Obsessive-Compulsive Disorder (OCD)

Psilocybin has exhibited promising results in treating obsessive-compulsive disorder (OCD) through facilitated introspection and changes in perception. Its action on serotonin receptors is believed to promote cognitive flexibility, reducing the grip of intrusive thoughts on patients and allowing for greater engagement in therapeutic processes. Preliminary trials support its safety and efficacy in diminishing OCD symptoms, opening pathways for further investigation.

View full Psilocybin profile →

MDMA and Obsessive-Compulsive Disorder (OCD)

Though primarily investigated for trauma-related disorders, MDMA also shows potential in enhancing therapeutic interactions and emotional resonance during psychotherapy for OCD. By promoting feelings of empathy and connection, MDMA may assist patients in confronting their compulsions within a supportive context, although specific studies on its efficacy for OCD are still emerging.

View full MDMA profile →

Key Insights

1
Recent evidence suggests that psilocybin can reduce OCD symptoms in treatment-resistant cases, offering a new hope for this challenging condition.
2
Psychedelics are thought to promote neuroplasticity and facilitate new perspectives, potentially addressing the rigid thought patterns inherent in OCD.
3
Existing clinical trials are exploring optimal dosing protocols and treatment regimens to enhance therapeutic outcomes for OCD patients.

Industrial Landscape

Key players in psychedelic OCD research include Stanford University's OCD Research Lab led by Carolyn Rodriguez and various non-profits such as the International OCD Foundation, which encourages research and awareness.

Quick Indicators

PrevalenceAbout 1-2% of the population worldwide.

Research Footprint

0Trials

0Papers

\"Ongoing clinical evaluations are investigating Obsessive-Compulsive Disorder (OCD) as a primary indication for various psychedelic compounds.\"

Key Organizations

4 Connected

Delix Therapeutics

Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.

MAPS

The description of the stakeholder

Lykos Therapeutics

Longer description of Lykos .. lorem ipsum ..

Leiden University

Leiden University doesn't have a dedicated research centre for psychedelics. However, several staff members from their medical centre and psychology faculty are working with psychedelics. Researchers here are working with other universities including Utrecht University as well as Compass Pathways.